# Primary Immune Thrombocytopenia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/primary-immune-thrombocytopenia

> 4 upcoming FDA catalysts in primary Immune Thrombocytopenia: efgartigimod ph20 sc (ARGX) on October 2027 (primary completion); efgartigimod ph20 sc (ARGX) on Oct 2027 to Jan 2028 (topline data readout); Nplate (romiplostim, AMGN) on Sep to Dec 2029 (topline data readout); Nplate (romiplostim, AMGN) on September 2029 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 19, 2025 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Primary Immune Thrombocytopenia | completed | "NCT05653219 (A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05653219)) |
| March 11, 2026 | [VYVGART (efgartigimod) primary completion](https://sec-api.dev/pdufa/efgartigimod) | ARGX | Primary Immune Thrombocytopenia | completed | "NCT04225156 (A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-11 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04225156)) |
| September 23, 2026 | [PF-06835375 primary completion](https://sec-api.dev/pdufa/pf-06835375) | PFE | Primary Immune Thrombocytopenia | withdrawn | "NCT05070845 (Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-23 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05070845)) |
| October 2027 | [Efgartigimod ph20 sc primary completion](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Primary Immune Thrombocytopenia | scheduled | "NCT04812925 (A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04812925)) |
| Oct 2027 to Jan 2028 | [Efgartigimod ph20 sc topline data readout](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) | ARGX | Primary Immune Thrombocytopenia | scheduled | "NCT04812925 (A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04812925)) |
| Sep to Dec 2029 | [Nplate (romiplostim) topline data readout](https://sec-api.dev/pdufa/romiplostim) | AMGN | Primary Immune Thrombocytopenia | scheduled | "NCT07700238 (A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-14 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07700238)) |
| September 2029 | [Nplate (romiplostim) primary completion](https://sec-api.dev/pdufa/romiplostim) | AMGN | Primary Immune Thrombocytopenia | scheduled | "NCT07700238 (A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-14 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07700238)) |

## Drugs

- [Ianalumab](https://sec-api.dev/pdufa/ianalumab) (NVS)
- [VYVGART (efgartigimod)](https://sec-api.dev/pdufa/efgartigimod) (ARGX)
- [PF-06835375](https://sec-api.dev/pdufa/pf-06835375) (PFE)
- [Efgartigimod ph20 sc](https://sec-api.dev/pdufa/efgartigimod-ph20-sc) (ARGX)
- [Nplate (romiplostim)](https://sec-api.dev/pdufa/romiplostim) (AMGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/primary-immune-thrombocytopenia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Primary Immune Thrombocytopenia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/primary-immune-thrombocytopenia

```bibtex
@misc{secapidev_indications_primary_immune_thrombocytopenia_20261116,
  title        = {Primary Immune Thrombocytopenia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/primary-immune-thrombocytopenia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_primary_immune_thrombocytopenia_20261116","title":"Primary Immune Thrombocytopenia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/primary-immune-thrombocytopenia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
